After ingesting the two articles a bit more I shared from Cleveland Clinic re: TNBC (interestingly the small case ‘m’ for metastatic isn’t included), here’s a few further thoughts…
From the Jan. 4, 2024 article:
“Current results from the phase 1 clinical trial of a novel vaccine under investigation at Cleveland Clinic were presented at the San Antonio Breast Cancer Symposium on December 6, 2023”
“The protein α-lactalbumin “is made in lactating breasts, but not at other times or in other tissues,” says Dr. Budd. In women past child-bearing age, α-lactalbumin is no longer expressed and is thus undetectable in normal, aging breast tissue. However, α-lactalbumin is expressed at high levels in more than 70% of TNBC tumors, and less frequently in some other breast cancers as well.
Dr. Tuohy’s research found that targeting α-lactalbumin in murine models was effective in preventing breast tumors and inhibited growth of existing breast tumors. These outcomes inspired the vaccine’s invention. “We are developing a vaccine against α-lactalbumin, trying to attack those cancer cells that make too much of this protein, thinking that because the protein is not being made unless the woman is lactating, then it should be safe,” Dr. Budd says.”
“Dr. Budd’s long-term hopes for the vaccine are that the risk of recurrence can be reduced in patients with TNBC and that the risk of getting TNBC at all can be decreased. “But I emphasize long-term,” he says, noting the lengthy process involved.”
And from the Nov 8, 2024 article:
“The trial is expected to begin in 2025 and is projected to last approximately two to three years.”
For added context, from 2021 when it started getting clinical…
October 26, 2021/Basic & Translational Science
Cleveland Clinic Launches First-of-its-Kind Preventive Breast Cancer Vaccine Study
https://consultqd.clevelandclinic.org/clevela...cine-study
“Cleveland Clinic has begun clinical testing of a novel vaccine designed ultimately to prevent triple-negative breast cancer (TNBC) by priming high-risk women to mount an immune response against a “retired” lactation protein expressed only in cancer cells.”
“Dr. Tuohy is the primary inventor of the vaccine technology, which Cleveland Clinic has licensed to Anixa Biosciences, Inc. He will receive a portion of commercialization revenues received by Cleveland Clinic for this technology and also holds personal equity in the company.”
From the Jan. 4, 2024 article:
“Current results from the phase 1 clinical trial of a novel vaccine under investigation at Cleveland Clinic were presented at the San Antonio Breast Cancer Symposium on December 6, 2023”
“The protein α-lactalbumin “is made in lactating breasts, but not at other times or in other tissues,” says Dr. Budd. In women past child-bearing age, α-lactalbumin is no longer expressed and is thus undetectable in normal, aging breast tissue. However, α-lactalbumin is expressed at high levels in more than 70% of TNBC tumors, and less frequently in some other breast cancers as well.
Dr. Tuohy’s research found that targeting α-lactalbumin in murine models was effective in preventing breast tumors and inhibited growth of existing breast tumors. These outcomes inspired the vaccine’s invention. “We are developing a vaccine against α-lactalbumin, trying to attack those cancer cells that make too much of this protein, thinking that because the protein is not being made unless the woman is lactating, then it should be safe,” Dr. Budd says.”
“Dr. Budd’s long-term hopes for the vaccine are that the risk of recurrence can be reduced in patients with TNBC and that the risk of getting TNBC at all can be decreased. “But I emphasize long-term,” he says, noting the lengthy process involved.”
And from the Nov 8, 2024 article:
“The trial is expected to begin in 2025 and is projected to last approximately two to three years.”
For added context, from 2021 when it started getting clinical…
October 26, 2021/Basic & Translational Science
Cleveland Clinic Launches First-of-its-Kind Preventive Breast Cancer Vaccine Study
https://consultqd.clevelandclinic.org/clevela...cine-study
“Cleveland Clinic has begun clinical testing of a novel vaccine designed ultimately to prevent triple-negative breast cancer (TNBC) by priming high-risk women to mount an immune response against a “retired” lactation protein expressed only in cancer cells.”
“Dr. Tuohy is the primary inventor of the vaccine technology, which Cleveland Clinic has licensed to Anixa Biosciences, Inc. He will receive a portion of commercialization revenues received by Cleveland Clinic for this technology and also holds personal equity in the company.”
1
